Neogen EV/EBIT NEOG

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 6.4×; Jan 2026
10-year median: 47.5×
10-year range: 3.4× to 221×
Peer median: 38.8×

Neogen has no meaningful EV/EBIT today: it made an operating loss of $7.4M over the last twelve months.

It was last meaningful in Jan 2026, at 6.4×.

On the days it had one over the last ten years, its median was 47.5×, from 3.4× in Apr 2025 to 221× in Feb 2023.

EV/EBIT over time

median 47.5×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	6.4×	6.4×	6.4×
2025	6.5×	3.4×	75.4×
2024	75.7×	44.5×	93.8×
2023	93.1×	33.0×	221×
2022	30.2×	19.6×	55.9×
2021	64.1×	50.1×	65.2×
2020	53.9×	39.4×	59.2×
2019	45.9×	38.0×	56.4×
2018	37.9×	31.8×	68.2×
2017	33.0×	25.7×	33.7×
2016	29.7×	20.1×	31.8×
2015	27.0×	21.3×	30.2×
2014	28.6×	21.8×	28.6×
2013	27.2×	20.3×	30.4×
2012	19.6×	18.3×	21.8×

Against its peers

Companies in Medical - Diagnostics & Research nearest Neogen's size, closest first, today.

Company	EV/EBIT
NEOGNeogen	n/m
CDNACareDx	29.3×
VCYTVeracyte	27.2×
BLLNBillionToOne	107×
LNTHLantheus	20.6×
CAICaris Life Sciences	56.4×
BIOBio-Rad Laboratories	40.2×
NRCNRC Health	38.8×
RVTYRevvity	46.0×
MEDPMedpace	31.4×
Peer median	38.8×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Neogen

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.